Citations

Clear

152 citation(s) found for "Tobin, M D".

NIMG-82. DEVELOPMENT AND VALIDATION OF AN MRI-BASED DEEP LEARNING MODEL TO DIFFERENTIATEIDH-WILDTYPE GLIOBLASTOMA AND TUMEFACTIVE MULTIPLE SCLEROSIS
Moassefi, Mana, Decker, Paul A. , Kosel, Matthew , Fereidan, Mah, Nikanpour, Yalda , Pump, Heather K., Jenkins, Robert B. , Eckel‐Passow, Jeanette E. , Conte, Gian Marco , Moassefi, Mana , Decker, Paul A. , McCarthy, Christina, Pump, Heather K. , Lachance, Daniel Honore , Erickson, Bradley J. , Tobin, W. Oliver

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii214-viii214

10.1093/neuonc/noae165.0846 Get It

Abstract Clinical management of IDH wildtype glioblastoma (GBM) and tumefactive multiple sclerosis (tMS) is drastically different. GBM requires maximal safe resection followed by chemoradiation, while tMS outcome is worsened by surgery and radiotherapy. Noninvasive methods are needed to help with accurate diagnosis of tumor and non-tumor etiologies. To develop an MRI-based classification model, tMS subjects diagnosed prior to January 1, 2020, were matched to tMS by age at diagnosis, sex, index MRI date, and 2D/3D acquisition. Inclusion criteria included one cm minimal lesion size and pre-operative post-contrast T1 and T2 images available for analysis. A 3D-DenseNet121 was used to develop a classification model using prespecified parameters: 650 epochs, batch size 16, learning rate 10-3, cross-entropy loss, and AdamW optimizer. The stopping rule was defined as three sequential differences in epoch cross-entropy loss <0.02. Models were developed using both T1gd and T2, as well as from only T1gd and only T2. Training included 220 subjects (110 GBM, 110 tMS). A 2-stage validation design was used, which included both retrospective and prospective cohorts. Stage 1 consisted of 272 retrospective GBM (diagnosed prior to January 1, 2020). Stage 2 consisted of 69 and 34 prospective (diagnosed after January 1, 2020) GBM and tMS, respectively. External validation on the 272 retrospective GBM demonstrated accuracy of 91%, 84%, and 78% for T1gd+T2, T1gd only, and T2 only, respectively. External validation on the 69 prospective GBM demonstrated an accuracy of 87%, 64%, and 67% for T1gd+T2, T1gd only, and T2 only, respectively. The 34 prospective tMS demonstrated accuracy of 76%, 76%, and 82% for T1gd+T2, T1gd only, and T2 only, respectively. This shows the feasibility of deep learning to aid in differential diagnosis of brain lesions. Future work entails the integration of germline variants into the classification model, including variants associated with the risk of glioma or MS.
EPID-19. INTERACTION BETWEEN GERMLINE AND SOMATIC GENETICS TO ELUCIDATE RISK OF ADULT DIFFUSE GLIOMA
Eckel‐Passow, Jeanette E. , Kosel, Matthew , Decker, Paul A. , Kollmeyer, Thomas M. , Molinaro, Annette M. , Wrensch, Margaret , Jenkins, Robert B. , Kollmeyer, Thomas , Decker, Paul A. , Drucker, Kristen , Molinaro, Annette M. , Francis, Stephen , Wiencke, John K. , Lachance, Daniel Honore , Tobin, W. Oliver

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii142-viii142

10.1093/neuonc/noae165.0555 Get It

Abstract Acquired tumor alterations are part of the WHO diagnosis of glioma. However, germline predisposition to these alterations is unknown. GWAS in European and Asian populations identified germline variants in 30 regions, many in or near genes that also acquire alterations, suggesting that interactions between inherited and acquired genetics are involved in glioma development. To evaluate such interactions, we used 3686 glioma cases and 1889 controls. A case-control design and multinomial logistic regression were used to identify germline variants associated with development of TERT-promoter mutant gliomas, generating two interesting observations. First, TERT germline variants were associated with predisposition to IDHwt glioma that have a TERT promoter mutation, but not with IDH-mutant codeleted gliomas that have a TERT promoter mutation. Second, two novel regions were observed in this more homogeneous subgroup of TERT mutated tumors: variants in TXNDC11 (OR=2.66, p=5.7x10-8) and RUVBL2 (OR=3.1, p=5.8x10-8). High tumor expression of TXNDC11 is associated with poor prognosis in glioma and RUVBL2 interacts with TERT to affect telomerase activity. Similar analyses are being performed on additional clinically relevant acquired alterations. In parallel, case-case GWAS analyses were performed to evaluate germline variants associated with other tumor alterations. Comparing IDH-mutant versus IDHwt stratified by rs55705857 genotype, the most significant variants were PHLDB1 (p=1.2x10-13) and D2HGDH (p=2.1x10-10), highlighting the importance of these two variants independent of CCDC26 for the development of IDH-mutant glioma. As a parallel approach, we utilized recursive partitioning and regression trees (rpart) to classify IDH mutation status using the 30 known variants. The top four branches of the regression tree included CCDC26, D2HGDH, PHLDB1, and MAML2, as well as two Asian variants (RAB27A, CYP4F12). This highlights the importance of utilizing variants discovered in non-European populations in analyses. Overall, understanding these interactions are necessary to develop therapeutics, stratify clinical trials, and to develop relevant tumor models.
Central nervous system crystal‐storing histiocytosis: A case report and literature review
Nathoo, Nabeela , Larson, Daniel P. , Guo, Yong , Lucchinetti, Claudia F. , Micallef, Ivana N. , Abeykoon, Jithma P. , Tobin, W Oliver , Nathoo, Nabeela , Giannini, Caterina , Rech, Karen L. , Jevremović, Dragan , Lachance, Daniel Honore , Go, Ronald S. , Tobin, W. Oliver

Mayo Clinic

European Journal of Neurology | October 26, 2024 | Volume: 32 | Issue: 1 | Pages: No page available

10.1111/ene.16528 | PMID 39460456 Get It

AbstractBackgroundCrystal‐storing histiocytosis (CSH) is a rare form of histiocytosis with intralysosomal accumulations of immunoglobulins or paraproteins that aggregate as crystals. Central nervous system (CNS) involvement of CSH is uncommon but should be considered in cases of persistent parenchymal enhancement on neuroimaging.MethodsWe describe one local case of CNS CSH and 10 additional cases identified by literature review.ResultsAmong 11 CSH patients, lesions involved either the dura (2/11) or brain parenchyma (9/11). Two cases had leptomeningeal enhancement. One case had spinal cord involvement. Two cases were associated with marginal zone lymphoma; one case was associated with an immunoglobulin A‐plasma cell dyscrasia. Eight of 11 cases had outcome data available: 7/8 cases had clinical and/or radiological improvement and 1/8 had radiological stability.ConclusionsCentral nervous system involvement of CSH is rare. Potential cases should be comprehensively evaluated for lymphoma or myeloma with positron emission tomography/computed tomography (CT) of the body or alternatively, CT of the chest, abdomen, pelvis and nuclear bone scan, bone marrow biopsy, serum protein electrophoresis, and cerebrospinal fluid protein electrophoresis. Treatment is targeted toward the underlying malignancy.
Intra-arterial Melphalan as Targeted Therapy for Tumefactive Multiple Sclerosis Lesions
Banks, Samantha A. , Brinjikji, Waleed , Xeros, Helena K., Toledano, Michel , Carabenciov, Ivan D. , Banks, Samantha , Giannini, Caterina , Syc‐Mazurek, Stephanie B. , Xeros, Helena , Mustafa, Rafid , Tobin, W. Oliver

Mayo Clinic

Neurology | August 6, 2024 | Volume: 103 | Issue: 5 | Pages: No page available

10.1212/wnl.0000000000209739 | PMID 39106425 Get It

Polyminimyoclonus in Hirayama Disease
Banks, Samantha A. , Ali, Farwa , Klassen, Bryan T. , Banks, Samantha , Clarke, Michelle J. , Tobin, W. Oliver

Mayo Clinic

Neurology | July 25, 2024 | Volume: 103 | Issue: 4 | Pages: No page available

10.1212/wnl.0000000000209740 | PMID 39052967 Get It

Cerebrospinal Fluid Cytokine and Chemokine Profiles in Central Nervous System Sarcoidosis: Diagnostic and Immunopathologic Insights
Mangioris, Georgios , Pittock, Sean J. , Yang, Binxia , Fryer, James P., Harmsen, William S. , Dubey, Divyanshu , López‐Chiriboga, A. Sebastian , McKeon, Andrew , Mills, John R. , Vodopivec, Ivana, Toledano, Michel , Aksamit, Allen J. , Ζεκερίδου, Αναστασία , Pittock, S J , Flanagan, E P , Lopez-Chiriboga, A Sebastian , McKeon, Andrew , Tobin, W Oliver , Toledano, Michel , Zekeridou, Anastasia , Dubey, Divyanshu , Yang, Binxia , Flanagan, Eoin P. , Tobin, W. Oliver

Mayo Clinic

Annals of Neurology | July 19, 2024 | Volume: 96 | Issue: 4 | Pages: 704-714

10.1002/ana.27024 | PMID 39031103 Get It

ObjectiveTo evaluate the cerebrospinal fluid (CSF) cytokine/chemokine profile of central nervous system (CNS) neurosarcoidosis (NS), and its utility in differential diagnosis, treatment, and prognostication.MethodsIn this case–control study, we validated 17 cytokines/chemokines (interleukin [IL]‐1‐beta, IL‐2, IL‐4, IL‐5, IL‐6, IL‐10, IL‐12p70, IL‐13, IL‐17A, BAFF, IL‐8/CXCL8, CXCL9, CXCL10, CXCL13, GM‐CSF, interferon‐gamma, and tumor necrosis factor [TNF]‐alpha) in a multiplexed automated immunoassay system (ELLA; Bio‐Techne, Minneapolis, MN, USA), and assessed them in CSF and serum of symptomatic patients with probable or definite CNS NS (01/2011–02/2023) with gadolinium enhancement and/or CSF pleocytosis. Patients with multiple sclerosis, primary CNS lymphoma, aquaporin‐4 immunoglobulin G positivity, non‐inflammatory disorders, and healthy individuals were used as controls.ResultsA total of 32 NS patients (59% women; median age, 59 years [19–81]) were included; concurrent sera were available in 12. CSF controls consisted of 26 multiple sclerosis, 8 primary CNS lymphoma, 84 aquaporin‐4 immunoglobulin G positive, and 34 patients with non‐inflammatory disorders. Gadolinium enhancement was present in 31 of 32 NS patients, and CSF pleocytosis in 27 of 32 (84%). CSF IL‐2, IL‐6, IL‐10, IL‐13, BAFF, IL‐8/CXCL8, CXCL9, CXCL10, CXCL13, GM‐CSF, interferon‐gamma, and TNF‐alpha levels were significantly higher in NS patients compared with non‐inflammatory controls (p ≤ 0.02); elevations were more common in CSF than serum. Concurrent elevation of IL‐6, CXCL9, CXCL10, GM‐CSF, interferon‐gamma, and TNF‐alpha was present in 18 of 32 NS patients, but only in 1 control. Elevated IL‐6, IL‐10, IL‐13, CXCL9, CXL10, GM‐CSF, and TNF‐alpha associated with measures of disease activity.InterpretationNS CSF cytokine/chemokine profiles suggest T cell (mainly T helper cell type 1), macrophage, and B‐cell involvement. These signatures aid in NS diagnosis, indicate disease activity, and suggest therapeutic avenues. ANN NEUROL 2024;96:704–714
Safety and efficacy of continuous terlipressin infusion in HRS-AKI in a transplant population
Reddy, K. Rajender , Izzy, Manhal , Frederick, R. Todd , Rubin, Raymond A. , Fricker, Zachary , Ikahihifo-Bender, Jade , Harte, Maggie , Garcia, Sandra, Campbell, Kathryn, Olofson, Amy , Razavi, Ryan F., James, Janelle M., Patel, Het , Kim-Lee, Grace, Witkiewicz, Sherry , Tobin, William, Jamil, Khurram , Weinberg, Ethan M , Gonzalez, Stevan A , Izzy, M , Simonetto, Douglas A , Frederick, R Todd , Rubin, Raymond A , Ikahihifo-Bender, Jade , Olofson, Amy , Kim-Lee, Grace , Witkiewicz, Sherry , Jamil, Khurram , Weinberg, Ethan M. , Simonetto, Douglas A.

Mayo Clinic

Liver Transplantation | May 21, 2024 | Volume: 30 | Issue: 10 | Pages: 1026-1038

10.1097/lvt.0000000000000399 | PMID 38771635 Get It

Hepatorenal syndrome-acute kidney injury (HRS-AKI) is associated with significant morbidity and mortality. While liver transplantation is the definitive treatment, continuous terlipressin infusion for HRS-AKI may provide benefit and, as such, was assessed in a population composed of candidates for liver transplant (LT). Fifty hospitalized LT-eligible patients with HRS-AKI received a single bolus followed by continuous terlipressin infusion. Acute-on-chronic liver failure grade 3, serum creatinine (SCr)>5.0 mg/dL, or Model for End-Stage Liver Disease (MELD) ≥35 were exclusions. Fifty hospitalized patients who received midodrine and octreotide or norepinephrine for HRS-AKI served as a historical comparator cohort. Complete response (CR) was defined as a ≥30% decrease in SCr with end-of-treatment (EOT) SCr≤1.5, partial response as a ≥30% decrease in SCr with EOT SCr>1.5, and nonresponse as a <30% decrease in SCr. CR rate was significantly higher in the terlipressin cohort compared to the historical cohort (64% vs. 16%, p<0.001). Survival, while numerically higher in those who received terlipressin, was statistically similar (D30: 94% vs. 82%, p=0.12; D90: 78% vs. 68%, p=0.37). Renal replacement therapy (RRT) was more common among terlipressin NR than CR and PR (70% vs. 3% vs. 13%, p < 0.001). EOT MELD and SCr were significantly lower within terlipressin cohort (MELD: 19 vs. 25, SCr: 1.4 vs. 2.1 mg/dL, p<0.001). Sixteen of 40 terlipressin-treated patients received LT-alone (terlipressin CR in 10/16). One patient on terlipressin had a hypoxic respiratory failure that responded to diuretics; one possibly had drug-related rash. With continuous terlipressin infusion, a CR rate of 64% was observed with a favorable safety profile. Terlipressin use was associated with lower EOT MELD and SCr than the historical midodrine and octreotide/norepinephrine cohort; LT-alone was accomplished in a high proportion of complete terlipressin responders.
Teaching NeuroImage: Fundoscopic and Optical Coherence Tomography Changes in Primary CNS Lymphoma
Moheb, Negar , Olsen, Timothy W. , Chen, John J. , Chen, John J , Tobin, W. Oliver

Mayo Clinic

Neurology | May 9, 2024 | Volume: 102 | Issue: 11 | Pages: No page available

10.1212/wnl.0000000000209512 | PMID 38723229 Get It

Abstract 306: Use of Real-Time Audiovisual CPR Feedback is Associated With Improved CPR Quality During Patient Transfer From the Scene to the Ambulance in Out-of-Hospital Cardiac Arrest
Vadeboncoeur, Tyler F. , Silver, Annemarie, Murphy, Ryan A. , Tobin, John, Venuti, Mark, Karamooz, Madalyn, Bobrow, Bentley J., Moon, Sungwoo , Spaite, Daniel W.

Mayo Clinic

Circulation | April 23, 2024 | Volume: 128 | Issue: suppl_22 | Pages: No page available

10.1161/circ.128.suppl_22.a306 Get It

Background: In the simulation setting, chest compression (CC) quality is reduced when out-of-hospital cardiac arrest “patients” are prepared for transport (i.e. packaged and moved to ambulance). It is unknown whether use of real-time audiovisual CPR feedback (RTAVF) affects manual CC quality when the patient is prepared for transport during actual out-of-hospital resuscitations. We tested the hypothesis that CC quality during patient transfer would be better when using RTAVF. Methods: CC quality was monitored at two EMS agencies using an E Series monitor/defibrillator with CC sensing capability (ZOLL Medical) during the treatment of consecutive out-of-hospital cardiac arrest patients who received CC on scene and were transported with ongoing CC. Data were collected during study phases; P1: RTAVF disabled, P2: RTAVF enabled following scenario-based training. Student’s t-test and Wilcoxon-Mann Whitney tests were used to compare CC quality in P1 vs. P2 during early scene and late scene treatment. Late scene was defined as the 3 minutes prior to transport (when packaging and transfer to the ambulance occurs) and early scene was all prior minutes at the scene. Results: 211 cardiac arrest cases were included: mean age 64±15 yrs, 67% male, 8% survival to hospital discharge. The Table shows that CC quality was superior during both early scene and late scene treatment in P2, when RTAVF was enabled, vs. P1, when RTAVF was disabled. Conclusion: CC quality, particularly the CC fraction, declines when a patient is packaged for transport and moved to the ambulance. While this decline is not prevented by RTAVF, CC quality during the late scene period is significantly better when using RTAVF. Further study is required to determine the impact of this improvement on outcomes.